Car Bruce 4

What Happened Car Bruce, Chief Scientific Officer of Biohaven Ltd. (BHVN), was granted a derivative award covering 175,000 shares on February 27, 2026. The filing reports an acquisition price of $0.00 (no cash paid at grant) and lists the transaction as an award/grant (derivative). The award is an option-like grant: the underlying shares vest in four equal annual installments (Feb 27, 2026–2029) subject to continuous service.

Key Details

• Transaction date: February 27, 2026; Form 4 filed March 3, 2026 (appears to be within the two-business-day reporting window).
• Transaction type: A — Grant/Award (derivative).
• Number of shares/units: 175,000 underlying shares.
• Reported price: $0.00 (no cash paid at grant); reported value = $0.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: “The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.”
• No indication in the filing that shares were immediately sold or that a 10b5-1 plan/gift/tax withholding applied.

Context This was a compensation-related, derivative award to an executive rather than an open-market purchase or sale. Such grants are commonly used for retention and incentive pay and do not represent an immediate investment of personal cash or a sale of shares. For investors, awards signal how the company compensates executives but are not direct buy/sell signals on their own.